Literature DB >> 23998028

Tuberculosis of larynx revisited: a report on clinical characteristics in 10 cases.

Sachin Gandhi1, Santosh Kulkarni, Prasun Mishra, Pallavi Thekedar.   

Abstract

Tuberculosis is the most frequent granulomatous disease involving larynx. In most cases it is secondary to pulmonary tuberculosis. Incidence of tuberculosis is now on a rise due to increase in incidence of immune deficiency states. Here we present a report of clinical characteristic of laryngeal tuberculosis based on our experience of 10 cases. A detailed retrospective analysis of 10 patients of laryngeal tuberculosis was done at our tertiary care laryngology centre. Majority of patients had change of voice and dry cough. All the patients had hyperemia and edema of vocal cords. 80% patients had involvement of the arytenoids and ary-epiglottic folds. Frank granulomatous growth was seen in 70% of patients. In all patients histopathological report was consistent with tubercular granuloma. Two patients had associated pulmonary tuberculosis. Eight patients did not reveal any feature suggestive of previous or co-existent pulmonary tuberculosis. All patients responded to chemotherapy with complete resolution. Primary laryngeal tuberculosis is not as rare as generally considered. This series provides an insight towards clinical feature, growth pattern and management of tuberculosis of larynx.

Entities:  

Keywords:  Laryngeal tuberculosis chemotherapy; Primary and secondary tuberculosis; Tuberculosis

Year:  2011        PMID: 23998028      PMCID: PMC3431514          DOI: 10.1007/s12070-011-0333-4

Source DB:  PubMed          Journal:  Indian J Otolaryngol Head Neck Surg        ISSN: 2231-3796


  6 in total

Review 1.  Inflammatory and granulomatous lesions of the larynx and pharynx.

Authors:  T A Loehrl; T L Smith
Journal:  Am J Med       Date:  2001-12-03       Impact factor: 4.965

2.  Epidemiological considerations and clinical features of ENT tuberculosis.

Authors:  N S Kulkarni; G S Gopal; S G Ghaisas; N A Gupte
Journal:  J Laryngol Otol       Date:  2001-07       Impact factor: 1.469

Review 3.  Atypical isolated epiglottic tuberculosis: a case report and a review of the literature.

Authors:  Jacopo Galli; Cristiano Nardi; Alessia M Contucci; Gabriella Cadoni; Libero Lauriola; M Fantoni
Journal:  Am J Otolaryngol       Date:  2002 Jul-Aug       Impact factor: 1.808

4.  Tuberculosis of the larynx: clinical aspects in 19 patients.

Authors:  A Soda; H Rubio; M Salazar; J Ganem; D Berlanga; A Sanchez
Journal:  Laryngoscope       Date:  1989-11       Impact factor: 3.325

5.  Upper respiratory tract tuberculosis. Sixteen cases in a general hospital.

Authors:  J J Rohwedder
Journal:  Ann Intern Med       Date:  1974-06       Impact factor: 25.391

6.  Laryngeal tuberculosis: an important diagnosis.

Authors:  M Harney; S Hone; C Timon; M Donnelly
Journal:  J Laryngol Otol       Date:  2000-11       Impact factor: 1.469

  6 in total
  3 in total

Review 1.  Quantity and Quality of Inhaled Dose Predicts Immunopathology in Tuberculosis.

Authors:  Kevin P Fennelly; Edward C Jones-López
Journal:  Front Immunol       Date:  2015-06-29       Impact factor: 7.561

2.  Evaluation of voice disorders in patients with active laryngeal tuberculosis.

Authors:  Marcia Mendonça Lucena; Fernanda Dos Santos da Silva; Ananda Dutra da Costa; Gabriela Rodrigues Guimarães; Ana Cristina Nunes Ruas; Frederico Pereira Bom Braga; Mateus Pereira Bom Braga; João Gustavo Corrêa Reis; Daniel César Silva da Costa; Mariana Reuter Palmeiro; Valéria Cavalcanti Rolla; Cláudia Maria Valete-Rosalino
Journal:  PLoS One       Date:  2015-05-26       Impact factor: 3.240

3.  Factors Associated with Clinical and Topographical Features of Laryngeal Tuberculosis.

Authors:  João Gustavo Corrêa Reis; Clarissa Souza Mota Reis; Daniel César Silva da Costa; Márcia Mendonça Lucena; Armando de Oliveira Schubach; Raquel de Vasconcellos Carvalhaes Oliveira; Valéria Cavalcanti Rolla; Fátima Conceição-Silva; Cláudia Maria Valete-Rosalino
Journal:  PLoS One       Date:  2016-04-14       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.